Poly(lactic acid)-based particulate systems are promising tools for immune modulation

Acta Biomaterialia

Volumn 48, Issue , 2017, Pages 41-57

  Peres, Carina ^a,b,c   Matos, Ana I ^a   Conniot, João ^a,d   Sainz, Vanessa ^a,d   Zupančič, Eva ^a   Silva, Joana M ^a,b   Graça, Luís ^c   Sá Gaspar, Rogério ^a   Préat, Véronique ^b   Florindo, Helena F ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adjuvant; Immune modulation; Microparticles; Nanoparticles; Poly(lactic acid); Vaccine

Indexed keywords

ANTIGENS; BIOCOMPATIBILITY; BIODEGRADABILITY; BIODEGRADABLE POLYMERS; DISEASE CONTROL; DISEASES; FUNCTIONAL POLYMERS; LACTIC ACID; MEDICAL APPLICATIONS; MODULATION; MOLECULES; NANOSYSTEMS; TUMORS;

ADJUVANT; BIOMEDICAL APPLICATIONS; IMMUNE CELLS; IMMUNE MODULATION; IN-VIVO; MICRO PARTICLES; POLY LACTIC ACID; POLY(LACTIC ACID); PROPERTY; VACCINE DELIVERY SYSTEM;

VACCINES;

BACTERIAL VACCINE; POLYLACTIC ACID; VIRUS VACCINE; NANOPARTICLE; POLYESTER; POLYLACTIDE; VACCINE;

DRUG DELIVERY SYSTEM; EX VIVO STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VIVO STUDY; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; DRUG EFFECTS; IMMUNITY;

ANIMALS; HUMANS; IMMUNITY; IMMUNOMODULATION; NANOPARTICLES; NANOTECHNOLOGY; POLYESTERS; VACCINES;

EID: 85006324780     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2016.11.012     Document Type: Review

References (222)

1. [1] Zepp, F., Principles of vaccine design—lessons from nature. Vaccine 28 (2010), C14–C24.
2. [2] Riedel, S., Edward Jenner and the history of smallpox and vaccination. Proceedings (Baylor University Medical Center) 18 (2005), 21–25.
3. [3] Plotkin, S.A., Plotkin, S.L., The development of vaccines: how the past led to the future. Nat. Rev. Micro. 9 (2011), 889–893.
4. [4] W.H. Organization, World health statistics 2015: World Health Organization, 2015.
5. [5] U. and W.H. Organization, Levels and trends in child mortality: Report: United Nations Children's Fund., 2015.
6. [6] Le Moigne, V., Rottman, M., Goulard, C., Barteau, B., Poncin, I., Soismier, N., Canaan, S., Pitard, B., Gaillard, J.L., Herrmann, J.L., Bacterial phospholipases C as vaccine candidate antigens against cystic fibrosis respiratory pathogens: the Mycobacterium abscessus model. Vaccine 33 (2015), 2118–2124.
7. [7] Grimwood, K., Kyd, J.M., Owen, S.J., Massa, H.M., Cripps, A.W., Vaccination against respiratory Pseudomonas aeruginosa infection. Human Vaccines Immunother. 11 (2015), 14–20.
8. [8] R.P. Alves, M.J. Yang, M.T. Batista, L.C. Ferreira. Alzheimer's disease: is a vaccine possible? Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica [et al.], vol. 47, 2014, pp. 438–444.
9. [9] Guo, W., Sha, S., Jiang, T., Xing, X., Cao, Y., A new DNA vaccine fused with the C3d–p28 induces a Th2 immune response against amyloid-beta. Neur. Regener. Res. 8 (2013), 2581–2590.
10. [10] Burton, D.R., Desrosiers, R.C., Doms, R.W., Koff, W.C., Kwong, P.D., Moore, J.P., Nabel, G.J., Sodroski, J., Wilson, I.A., Wyatt, R.T., HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 (2004), 233–236.
11. [11] Rose, N.F., Marx, P.A., Luckay, A., Nixon, D.F., Moretto, W.J., Donahoe, S.M., Montefiori, D., Roberts, A., Buonocore, L., Rose, J.K., An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 (2001), 539–549.
12. [12] Silva, J.M., Zupancic, E., Vandermeulen, G., Oliveira, V.G., Salgado, A., Videira, M., Gaspar, M., Graca, L., Preat, V., Florindo, H.F., In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model. J. Control. Release: Off. J. Control. Release Soc. 198 (2015), 91–103.
13. [13] Cheever, M.A., Higano, C.S., PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Can. Res.: Off. J. Am. Assoc. Can. Res. 17 (2011), 3520–3526.
14. [14] Quintero, I.B., Araujo, C.L., Pulkka, A.E., Wirkkala, R.S., Herrala, A.M., Eskelinen, E.L., Jokitalo, E., Hellstrom, P.A., Tuominen, H.J., Hirvikoski, P.P., Vihko, P.T., Prostatic acid phosphatase is not a prostate specific target. Cancer Res. 67 (2007), 6549–6554.
15. [15] Dimier-Poisson, I., Carpentier, R., N'Guyen, T.T.L., Dahmani, F., Ducournau, C., Betbeder, D., Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection. Biomaterials 50 (2015), 164–175.
16. [16] Foged, C., Hansen, J., Agger, E.M., License to kill: formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. Europ. J. Pharmaceut. Sci.: Off. J. Europ. Feder. Pharmaceut. Sci. 45 (2012), 482–491.
17. [17] Ulmer, J.B., Valley, U., Rappuoli, R., Vaccine manufacturing: challenges and solutions. Nat. Biotech. 24 (2006), 1377–1383.
18. [18] M.C. McCormick, D.A. Almario, K. Stratton, I. Medicine, I.S.R. Committee, B.H.P.D. Prevention. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer: National Academies Press, 2003.
19. [19] Harasawa, R., Tomiyama, T., Evidence of pestivirus RNA in human virus vaccines. J. Clin. Microbiol. 32 (1994), 1604–1605.
20. [20] Cutrone, R., Lednicky, J., Dunn, G., Rizzo, P., Bocchetta, M., Chumakov, K., Minor, P., Carbone, M., Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res. 65 (2005), 10273–10279.
21. [21] Pliaka, V., Kyriakopoulou, Z., Markoulatos, P., Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev. Vaccines 11 (2012), 609–628.
22. [22] Lee, S.-W., Markham, P.F., Coppo, M.J., Legione, A.R., Markham, J.F., Noormohammadi, A.H., Browning, G.F., Ficorilli, N., Hartley, C.A., Devlin, J.M., Attenuated vaccines can recombine to form virulent field viruses. Science, 337, 2012, 188.
23. [23] Pavot, V., Berthet, M., Resseguier, J., Legaz, S., Handke, N., Gilbert, S.C., Paul, S., Verrier, B., Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery. Nanomedicine (London, England) 9 (2014), 2703–2718.
24. [24] De Temmerman, M.L., Rejman, J., Demeester, J., Irvine, D.J., Gander, B., De Smedt, S.C., Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discovery Today 16 (2011), 569–582.
25. [25] T.J. Kindt, R.A. Goldsby, B.A. Osborne, J. Kuby. Kuby Immunology: W.H. Freeman, 2007.
26. [26] Baylor, N.W., Egan, W., Richman, P., Aluminum salts in vaccines—US perspective. Vaccine 20:Supplement 3 (2002), S18–S23.
27. [27] Chen, X., Kim, P., Farinelli, B., Doukas, A., Yun, S.H., Gelfand, J.A., Anderson, R.R., Wu, M.X., A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS ONE, 5, 2010, e13776.
28. [28] Zhang, W., Wang, L., Liu, Y., Chen, X., Liu, Q., Jia, J., Yang, T., Qiu, S., Ma, G., Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials 35 (2014), 6086–6097.
29. [29] R.D. Weeratna, M.J. McCluskie, Recent Advances in Vaccine Adjuvants, in: A.A. Miller, P.F. Miller (Eds.), Emerging Trends in Antibacterial Discovery: Answering the Call to Arms, Horizon Scientific Press; 2011, pp. 313–322.
30. [30] Goto, N., Kato, H., Maeyama, J., Eto, K., Yoshihara, S., Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 11 (1993), 914–918.
31. [31] Seubert, A., Monaci, E., Pizza, M., O'Hagan, D.T., Wack, A., The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. (Baltimore, Md: 1950) 180 (2008), 5402–5412.
32. [32] Morel, S., Didierlaurent, A., Bourguignon, P., Delhaye, S., Baras, B., Jacob, V., Planty, C., Elouahabi, A., Harvengt, P., Carlsen, H., Kielland, A., Chomez, P., Garcon, N., Van Mechelen, M., Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29 (2011), 2461–2473.
33. [33] Didierlaurent, A.M., Morel, S., Lockman, L., Giannini, S.L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., Larocque, D., Van Mechelen, M., Garcon, N., AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. (Baltimore, Md: 1950) 183 (2009), 6186–6197.
34. [34] Tritto, E., Mosca, F., De Gregorio, E., Mechanism of action of licensed vaccine adjuvants. Vaccine 27 (2009), 3331–3334.
35. [35] Del Giudice, G., Fragapane, E., Bugarini, R., Hora, M., Henriksson, T., Palla, E., O'Hagan, D., Donnelly, J., Rappuoli, R., Podda, A., Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin. Vaccine Immunol.: CVI 13 (2006), 1010–1013.
36. [36] Montomoli, E., Piccirella, S., Khadang, B., Mennitto, E., Camerini, R., De Rosa, A., Current adjuvants and new perspectives in vaccine formulation. Expert Rev. Vaccines 10 (2011), 1053–1061.
37. [37] Zhao, Z., Leong, K.W., Controlled delivery of antigens and adjuvants in vaccine development. J. Pharm. Sci. 85 (1996), 1261–1270.
38. [38] Silva, J.M., Vandermeulen, G., Oliveira, V.G., Pinto, S.N., Rodrigues, C., Salgado, A., Afonso, C.A., Viana, A.S., Jérôme, C., Silva, L.C., Florindo, H.F., Development of functionalized nanoparticles for vaccine delivery to dendritic cells: a mechanistic approach. Nanomedicine 9 (2014), 2639–2656.
39. [39] Akagi, T., Baba, M., Akashi, M., Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine. Kunugi, S., Yamaoka, T., (eds.) Polymers in Nanomedicine, 2012, Springer, Berlin, Heidelberg, 31–64.
40. [40] Singh, M., Singh, O., Singh, A., Talwar, G.P., Immunogenicity studies on diphtheria toxoid loaded biodegradable microspheres. Int. J. Pharm. 85 (1992), R5–R8.
41. [41] Desai, K.G., Schwendeman, S.P., Active self-healing encapsulation of vaccine antigens in PLGA microspheres. J. Control. Release: Off. J. Control. Release Soc. 165 (2013), 62–74.
42. [42] A.-C. Albertsson, I. Varma, Aliphatic Polyesters: Synthesis, Properties and Applications, Degradable Aliphatic Polyesters, Springer, Berlin, Heidelberg; 2002, pp. 1–40.
43. [43] Zhao, L., Li, N., Wang, K., Shi, C., Zhang, L., Luan, Y., A review of polypeptide-based polymersomes. Biomaterials 35 (2014), 1284–1301.
44. [44] Danhier, F., Ansorena, E., Silva, J.M., Coco, R., Le Breton, A., Préat, V., PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release: Off. J. Control. Release Soc. 161 (2012), 505–522.
45. [45] Lasprilla, A.J.R., Martinez, G.A.R., Lunelli, B.H., Jardini, A.L., Filho, R.M., Poly-lactic acid synthesis for application in biomedical devices - a review. Biotechnol. Adv. 30 (2012), 321–328.
46. [46] Shive, M.S., Anderson, J.M., Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28 (1997), 5–24.
47. [47] Chaplin, D.D., Overview of the immune response. J. Allergy Clin. Immunol. 125 (2010), S3–S23.
48. [48] Kah-Wai, L., Jacek, T., Jacek, R., Dendritic cells heterogeneity and its role in cancer immunity. J. Cancer Res. Ther. 2 (2006), 35–40.
49. [49] Fajardo-Moser, M., Berzel, S., Moll, H., Mechanisms of dendritic cell-based vaccination against infection. Int. J. Med. Microbiol.: IJMM 298 (2008), 11–20.
50. [50] Faith, A., Hawrylowicz, C.M., Targeting the dendritic cell: the key to immunotherapy in cancer?. Clin. Exp. Immunol. 139 (2005), 395–397.
51. [51] S.N. Markovic, L.A. Erickson, R.D. Rao, R.H. Weenig, B.A. Pockaj, A. Bardia, C.M. Vachon, S.E. Schild, R.R. McWilliams, J.L. Hand. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clinic Proceedings, Elsevier, 2007, pp. 490–513.
52. [52] Kim, J., Mooney, D.J., In Vivo modulation of dendritic cells by engineered materials: towards new cancer vaccines. Nano Today 6 (2011), 466–477.
53. [53] Kalinski, P., Dendritic cells in immunotherapy of established cancer: roles of signals 1, 2, 3 and 4. Curr. Opin. Investig. Drugs, 10, 2009, 526.
54. +T cells: differentiation and functions. Clin. Dev. Immunol., 12, 2012.
55. [55] Parkin, J., Cohen, B., An overview of the immune system. The Lancet 357 (2001), 1777–1789.
56. [56] Watts, C., The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat. Immunol. 5 (2004), 685–692.
57. [57] Frazer, I.H., Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 4 (2004), 46–55.
58. [58] Amigorena, S., Savina, A., Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr. Opin. Immunol. 22 (2010), 109–117.
59. [59] Vyas, J.M., Van der Veen, A.G., Ploegh, H.L., The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 8 (2008), 607–618.
60. [60] Palucka, K., Banchereau, J., Dendritic-cell-based therapeutic cancer vaccines. Immunity 39 (2013), 38–48.
61. [61] Arens, R., Schoenberger, S.P., Plasticity in programming of effector and memory CD8+ T-cell formation. Immunol. Rev. 235 (2010), 190–205.
62. [62] Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., Levitsky, H., The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188 (1998), 2357–2368.
63. [63] Conniot, J., Silva, J.M., Fernandes, J.G., Silva, L.C., Gaspar, R., Brocchini, S., Florindo, H.F., Barata, T.S., Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front. Chem., 2, 2014, 105.
64. [64] Kim, B.Y., Rutka, J.T., Chan, W.C., Nanomedicine. New Engl. J. Med. 363 (2010), 2434–2443.
65. [65] Ferrari, M., Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5 (2005), 161–171.
66. [66] Toy, R., Bauer, L., Hoimes, C., Ghaghada, K.B., Karathanasis, E., Targeted nanotechnology for cancer imaging. Adv. Drug Deliv. Rev. 76 (2014), 79–97.
67. [67] Xu, H., Li, Z., Si, J., Nanocarriers in gene therapy: a review. J. Biomed. Nanotechnol. 10 (2014), 3483–3507.
68. [68] Khang, D., Carpenter, J., Chun, Y., Pareta, R., Webster, T., Nanotechnology for regenerative medicine. Biomed. Microdev. 12 (2010), 575–587.
69. [69] Rawat, M., Singh, D., Saraf, S., Saraf, S., Nanocarriers: promising vehicle for bioactive drugs. Biol. Pharm. Bull. 29 (2006), 1790–1798.
70. [70] Zhang, X., Guo, Q., Cui, D., Recent advances in nanotechnology applied to biosensors. Sensors (Basel) 9 (2009), 1033–1053.
71. [71] Jain, K.K., Nanomedicine: application of nanobiotechnology in medical practice. Medical principles and practice. Int. J. Kuwait Univ., Health Sci. Centre 17 (2008), 89–101.
72. [72] Lammers, T., Aime, S., Hennink, W.E., Storm, G., Kiessling, F., Theranostic nanomedicine. Acc. Chem. Res. 44 (2011), 1029–1038.
73. [73] Farokhzad, O.C., Langer, R., Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev. 58 (2006), 1456–1459.
74. [74] Mishra, B., Patel, B.B., Tiwari, S., Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 6 (2010), 9–24.
75. [75] Gregory, A.E., Titball, R., Williamson, D., Vaccine delivery using nanoparticles. Front. Cell. Infect. Microbiol., 3, 2013, 13.
76. [76] van Vlerken, L.E., Vyas, T.K., Amiji, M.M., Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 24 (2007), 1405–1414.
77. [77] Gelperina, S., Kisich, K., Iseman, M.D., Heifets, L., The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am. J. Respir. Crit. Care Med. 172 (2005), 1487–1490.
78. [78] Malyala, P., Singh, M., Micro/nanoparticle adjuvants: preparation and formulation with antigens. Methods Mole. Biol. (Clifton, NJ) 626 (2010), 91–101.
79. [79] Esparza, I., Kissel, T., Parameters affecting the immunogenicity of microencapsulated tetanus toxoid. Vaccine 10 (1992), 714–720.
80. [80] Kumari, A., Yadav, S.K., Yadav, S.C., Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerf. 75 (2010), 1–18.
81. [81] Hans, M., Lowman, A., Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 6 (2002), 319–327.
82. [82] Singh, R., Lillard, J.W. Jr., Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86 (2009), 215–223.
83. [83] Grislain, L., Couvreur, P., Lenaerts, V., Roland, M., Deprez-Decampeneere, D., Speiser, P., Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 15 (1983), 335–345.
84. [84] Noble, G.T., Stefanick, J.F., Ashley, J.D., Kiziltepe, T., Bilgicer, B., Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 32 (2014), 32–45.
85. [85] Mitragotri, S., Burke, P.A., Langer, R., Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discovery 13 (2014), 655–672.
86. [86] Madhavan Nampoothiri, K., Nair, N.R., John, R.P., An overview of the recent developments in polylactide (PLA) research. Bioresour. Technol. 101 (2010), 8493–8501.
87. [87] B.K. Lee, Y. Yun, K. Park. PLA micro- and nano-particles. Advanced Drug Delivery Reviews.
88. [88] Gaspar, R.S., Therapeutic products: regulating drugs and medical devices. Hodge, G.A., Bowman, D.M., Maynard, A.D., (eds.) International Handbook on Regulating Nanotechnologies, 2010, Edward Elgar Publishing Limited, Northampton, MA, USA, 291–320.
89. [89] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Q8, Pharmaceutical Development. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Tripartite Guideline, ICH, Geneva, 2009.
90. [90] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Q9, Quality Risk Management. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Tripartite Guideline, ICH, Geneva, 2005.
91. [91] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Q10, Pharmaceutical Quality System. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Tripartite Guideline, ICH, Geneva, 2008.
92. [92] Shakya, A.K., Nandakumar, K.S., Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases. J. Roy. Soc., Interf./Roy. Soc., 10, 2013, 20120536.
93. [93] Torchilin, V., Intracellular delivery of protein and peptide therapeutics. Drug Discov. Today Technol. 5 (2008), e95–e103.
94. [94] Vlieghe, P., Lisowski, V., Martinez, J., Khrestchatisky, M., Synthetic therapeutic peptides: science and market. Drug Discovery Today 15 (2010), 40–56.
95. [95] Demento, S.L., Cui, W., Criscione, J.M., Stern, E., Tulipan, J., Kaech, S.M., Fahmy, T.M., Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 33 (2012), 4957–4964.
96. [96] Oyewumi, M.O., Kumar, A., Cui, Z., Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 9 (2010), 1095–1107.
97. [97] Kaisho, T., Akira, S., Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta 1589 (2002), 1–13.
98. [98] Lettiero, B., Andersen, A.J., Hunter, A.C., Moghimi, S.M., Complement system and the brain: selected pathologies and avenues toward engineering of neurological nanomedicines. J. Control. Release: Off. J. Control. Release Soc. 161 (2012), 283–289.
99. [99] Thomasin, C., Corradin, G., Men, Y., Merkle, H.P., Gander, B., Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J. Control. Release 41 (1996), 131–145.
100. [100] Alonso, M.J., Cohen, S., Park, T.G., Gupta, R.K., Siber, G.R., Langer, R., Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm. Res. 10 (1993), 945–953.
101. [101] Sanchez, A., Gupta, R.K., Alonso, M.J., Siber, G.R., Langer, R., Pulsed controlled-release system for potential use in vaccine delivery. J. Pharm. Sci. 85 (1996), 547–552.
102. [102] Beier, R., Gebert, A., Kinetics of particle uptake in the domes of Peyer's patches. Am. J. Physiol. 275 (1998), G130–G137.
103. [103] Mohanan, D., Slutter, B., Henriksen-Lacey, M., Jiskoot, W., Bouwstra, J.A., Perrie, Y., Kundig, T.M., Gander, B., Johansen, P., Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J. Control. Release: Off. J. Control. Release Soc. 147 (2010), 342–349.
104. [104] Trombetta, E.S., Mellman, I., Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23 (2005), 975–1028.
105. [105] Stils, H.F., Adjuvants and antibody production: dispelling the myths associated with freund's complete and other adjuvants. ILAR J. 46 (2005), 280–293.
106. [106] Cruz, L.J., Tacken, P.J., Fokkink, R., Joosten, B., Stuart, M.C., Albericio, F., Torensma, R., Figdor, C.G., Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control. Release 144 (2010), 118–126.
107. [107] Gamvrellis, A., Leong, D., Hanley, J.C., Xiang, S.D., Mottram, P., Plebanski, M., Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol. 82 (2004), 506–516.
108. [108] Sahay, G., Alakhova, D.Y., Kabanov, A.V., Endocytosis of nanomedicines. J. Control. Release: Off. J. Control. Release Soc. 145 (2010), 182–195.
109. [109] Ehrlich, M., Boll, W., Van Oijen, A., Hariharan, R., Chandran, K., Nibert, M.L., Kirchhausen, T., Endocytosis by random initiation and stabilization of clathrin-coated pits. Cell 118 (2004), 591–605.
110. [110] Wang, Z., Tiruppathi, C., Minshall, R.D., Malik, A.B., Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. ACS Nano 3 (2009), 4110–4116.
111. [111] Wilson, N.S., El-Sukkari, D., Belz, G.T., Smith, C.M., Steptoe, R.J., Heath, W.R., Shortman, K., Villadangos, J.A., Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 102 (2003), 2187–2194.
112. [112] Manolova, V., Flace, A., Bauer, M., Schwarz, K., Saudan, P., Bachmann, M.F., Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38 (2008), 1404–1413.
113. [113] Idoyaga, J., Fiorese, C., Zbytnuik, L., Lubkin, A., Miller, J., Malissen, B., Mucida, D., Merad, M., Steinman, R.M., Specialized role of migratory dendritic cells in peripheral tolerance induction. J. Clin. Investig. 123 (2013), 844–854.
114. [114] Leleux, J., Roy, K., Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective. Adv. Healthcare Mater. 2 (2013), 72–94.
115. [115] Park, Y.M., Lee, S.J., Kim, Y.S., Lee, M.H., Cha, G.S., Jung, I.D., Kang, T.H., Han, H.D., Nanoparticle-based vaccine delivery for cancer immunotherapy. Immune Network 13 (2013), 177–183.
116. [116] Fahmy, T.M., Samstein, R.M., Harness, C.C., Mark, W., Saltzman. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 26 (2005), 5727–5736.
117. [117] Duncanson, W.J., Figa, M.A., Hallock, K., Zalipsky, S., Hamilton, J.A., Wong, J.Y., Targeted binding of PLA microparticles with lipid-PEG-tethered ligands. Biomaterials 28 (2007), 4991–4999.
118. [118] van Kooyk, Y., C-type lectins on dendritic cells: key modulators for the induction of immune responses. Biochem. Soc. Trans. 36 (2008), 1478–1481.
119. [119] Bandyopadhyay, A., Fine, R.L., Demento, S., Bockenstedt, L.K., Fahmy, T.M., The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials 32 (2011), 3094–3105.
120. [120] Sehgal, K., Ragheb, R., Fahmy, T.M., Dhodapkar, M.V., Dhodapkar, K.M., Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk. J. Immunol. (Baltimore, Md: 1950) 193 (2014), 2297–2305.
121. [121] Chappell, C.P., Giltiay, N.V., Dresch, C., Clark, E.A., Controlling immune responses by targeting antigens to dendritic cell subsets and B cells. Int. Immunol. 26 (2014), 3–11.
122. [122] van Broekhoven, C.L., Parish, C.R., Demangel, C., Britton, W.J., Altin, J.G., Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 64 (2004), 4357–4365.
123. [123] Uto, T., Wang, X., Sato, K., Haraguchi, M., Akagi, T., Akashi, M., Baba, M., Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J. Immunol. (Baltimore, Md: 1950) 178 (2007), 2979–2986.
124. [124] Mofazzal Jahromi, M.A., Karimi, M., Azadmanesh, K., Naderi Manesh, H., Hassan, Z.M., Moazzeni, S.M., The effect of chitosan-tripolyphosphate nanoparticles on maturation and function of dendritic cells. Comp. Clin. Pathol. 23 (2014), 1421–1427.
125. [125] Foged, C., Brodin, B., Frokjaer, S., Sundblad, A., Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm. 298 (2005), 315–322.
126. [126] Vasir, J.K., Labhasetwar, V., Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. Biomaterials 29 (2008), 4244–4252.
127. [127] Albanese, A., Tang, P.S., Chan, W.C., The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14 (2012), 1–16.
128. [128] Knudsen, K.B., Northeved, H., Kumar, P.E., Permin, A., Gjetting, T., Andresen, T.L., Larsen, S., Wegener, K.M., Lykkesfeldt, J., Jantzen, K., Loft, S., Moller, P., Roursgaard, M., In vivo toxicity of cationic micelles and liposomes. Nanomedicine 11 (2015), 467–477.
129. [129] Cho, E.C., Zhang, Q., Xia, Y., The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nat. Nanotechnol. 6 (2011), 385–391.
130. [130] Cruz, L.J., Tacken, P.J., Fokkink, R., Figdor, C.G., The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials 32 (2011), 6791–6803.
131. [131] Kumari, A., Yadav, S.K., Cellular interactions of therapeutically delivered nanoparticles. Exp. Opin. Drug Deliv. 8 (2011), 141–151.
132. [132] Danhier, F., Feron, O., Preat, V., To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release: Off. J. Control. Release Soc. 148 (2010), 135–146.
133. [133] Mundargi, R.C., Babu, V.R., Rangaswamy, V., Patel, P., Aminabhavi, T.M., Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J. Control. Release: Off. J. Control. Release Soc. 125 (2008), 193–209.
134. [134] Weissleder, R., Kelly, K., Sun, E.Y., Shtatland, T., Josephson, L., Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23 (2005), 1418–1423.
135. [135] Liu, G., Zhang, L., Zhao, Y., Modulation of immune responses through direct activation of Toll-like receptors to T cells. Clin. Exp. Immunol. 160 (2010), 168–175.
136. [136] Cruz, L.J., Tacken, P.J., Fokkink, R., Joosten, B., Stuart, M.C., Albericio, F., Torensma, R., Figdor, C.G., Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control. Release: Off. J. Control. Release Soc. 144 (2010), 118–126.
137. [137] Betancourt, T., Byrne, J.D., Sunaryo, N., Crowder, S.W., Kadapakkam, M., Patel, S., Casciato, S., Brannon-Peppas, L., PEGylation strategies for active targeting of PLA/PLGA nanoparticles. J. Biomed. Mater. Res., Part A 91 (2009), 263–276.
138. [138] E. Soto, G. Ostroff, Glucan Particles as Carriers of Nanoparticles for Macrophage-Targeted Delivery, Nanomaterials for Biomedicine: American Chemical Society, 2012, pp. 57–79.
139. [139] Woodruff, M.A., Hutmacher, D.W., The return of a forgotten polymer—polycaprolactone in the 21st century. Prog. Polym. Sci. 35 (2010), 1217–1256.
140. [140] Storni, T., Kundig, T.M., Senti, G., Johansen, P., Immunity in response to particulate antigen-delivery systems. Adv. Drug Deliv. Rev. 57 (2005), 333–355.
141. [141] Cohen-Erez, I., Rapaport, H., Coassemblies of the anionic polypeptide gamma-PGA and cationic beta-sheet peptides for drug delivery to mitochondria. Biomacromolecules 16 (2015), 3827–3835.
142. [142] Rimessi, P., Sabatelli, P., Fabris, M., Braghetta, P., Bassi, E., Spitali, P., Vattemi, G., Tomelleri, G., Mari, L., Perrone, D., Medici, A., Neri, M., Bovolenta, M., Martoni, E., Maraldi, N.M., Gualandi, F., Merlini, L., Ballestri, M., Tondelli, L., Sparnacci, K., Bonaldo, P., Caputo, A., Laus, M., Ferlini, A., Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the MDX mouse. Mole. Therapy: J. Am. Soc. Gene Ther. 17 (2009), 820–827.
143. [143] Florindo, H.F., Pandit, S., Goncalves, L.M., Alpar, H.O., Almeida, A.J., Surface modified polymeric nanoparticles for immunisation against equine strangles. Int. J. Pharm. 390 (2010), 25–31.
144. [144] Panyam, J., Labhasetwar, V., Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55 (2003), 329–347.
145. [145] Peek, L.J., Middaugh, C.R., Berkland, C., Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60 (2008), 915–928.
146. [146] Bishop, C.J., Ketola, T.M., Tzeng, S.Y., Sunshine, J.C., Urtti, A., Lemmetyinen, H., Vuorimaa-Laukkanen, E., Yliperttula, M., Green, J.J., The effect and role of carbon atoms in poly(beta-amino ester)s for DNA binding and gene delivery. J. Am. Chem. Soc. 135 (2013), 6951–6957.
147. [147] Bishop, C.J., Abubaker-Sharif, B., Guiriba, T., Tzeng, S.Y., Green, J.J., Gene delivery polymer structure-function relationships elucidated via principal component analysis. Chem. Commun. (Cambridge, England) 51 (2015), 12134–12137.
148. [148] R.A. Auras, L.T. Lim, S.E.M. Selke, H. Tsuji. Poly(lactic acid): Synthesis, Structures, Properties, Processing, and Applications, Wiley, 2011.
149. [149] Lopes, M.S., Jardini, A.L., Filho, R.M., Poly (Lactic Acid) production for tissue engineering applications. Proced. Eng. 42 (2012), 1402–1413.
150. [150] Lassalle, V., Ferreira, M.L., PLA nano- and microparticles for drug delivery: an overview of the methods of preparation. Macromol. Biosci. 7 (2007), 767–783.
151. [151] Lampe, K.J., Namba, R.M., Silverman, T.R., Bjugstad, K.B., Mahoney, M.J., Impact of lactic acid on cell proliferation and free radical-induced cell death in monolayer cultures of neural precursor cells. Biotechnol. Bioeng. 103 (2009), 1214–1223.
152. [152] McKeen, L.W., 3 - Plastics Used in Medical Devices A2 - Modjarrad, Kayvon. Ebnesajjad, S., (eds.) Handbook of Polymer Applications in Medicine and Medical Devices, 2014, William Andrew Publishing, Oxford, 21–53.
153. [153] Ali, M., Brocchini, S., Synthetic approaches to uniform polymers. Adv. Drug Deliv. Rev. 58 (2006), 1671–1687.
154. [154] Nobs, L., Buchegger, F., Gurny, R., Allemann, E., Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods. Int. J. Pharm. 250 (2003), 327–337.
155. [155] Nobs, L., Buchegger, F., Gurny, R., Allemann, E., Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting. Europ. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 58 (2004), 483–490.
156. [156] L.T. Sin, A.R. Rahmat, W.A. Rahman, Polylactic acid: PLA Biopolymer Technology and Applications, William Andrew, 2012.
157. [157] H. Benninga, A History of Lactic acid Making: A Chapter in the History of Biotechnology: Springer Science & Business Media, 1990.
158. [158] L. Avérous, Polylactic acid: synthesis, properties and applications. In: M. Belgacem, A. Gandini (Eds.), Monomers, Polymers and Composites from Renewable Resources, Elsevier, 2008, pp. 433–450.
159. [159] Garlotta, D., A literature review of poly(Lactic Acid). J. Polym. Environ. 9 (2001), 63–84.
160. [160] Drumright, R.E., Gruber, P.R., Henton, D.E., Polylactic acid technology. Adv. Mater. 12 (2000), 1841–1846.
161. [161] Hudson, D., Margaritis, A., Biopolymer nanoparticle production for controlled release of biopharmaceuticals. Crit. Rev. Biotechnol. 34 (2014), 161–179.
162. [162] Anderson, J.M., Shive, M.S., Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 64:Supplement (2012), 72–82.
163. [163] Garay, R.P., El-Gewely, R., Armstrong, J.K., Garratty, G., Richette, P., Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Deliv. 9 (2012), 1319–1323.
164. [164] U. Edlund, A.C. Albertsson, Degradable Polymer Microspheres for Controlled Drug Delivery. Degradable Aliphatic Polyesters, Springer, Berlin, Heidelberg, 2002, pp. 67–112.
165. [165] Arshady, R., Biodegradable polymers: concepts, criteria, and definitions. Arshady, R., (eds.) Biodegradable Polymers, the PBM Series, 2003, Citus Ltd, London, 2–34.
166. [166] Athanasiou, K.A., Niederauer, G.G., Agrawal, C.M., Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 17 (1996), 93–102.
167. [167] Orozco, V., Palacio, J., Sierra, J., López, B., Increased covalent conjugation of a model antigen to poly(lactic acid)-g-maleic anhydride nanoparticles compared to bare poly(lactic acid) nanoparticles. Colloid. Polym. Sci. 291 (2013), 2775–2781.
168. [168] Dixit, S., Singh, S.R., Yilma, A.N., Agee, R.D. 2nd, Taha, M., Dennis, V.A., Poly(lactic acid)–poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice. Nanomedicine 10 (2014), 1311–1321.
169. [169] Bergquist, C., Johansson, E.L., Lagergard, T., Holmgren, J., Rudin, A., Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect. Immun. 65 (1997), 2676–2684.
170. [170] Liang, B., Hyland, L., Hou, S., Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice. J. Virol. 75 (2001), 5416–5420.
171. [171] Eyles, J.E., Sharp, G.J., Williamson, E.D., Spiers, I.D., Alpar, H.O., Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 16 (1998), 698–707.
172. [172] Neutra, M.R., Pringault, E., Kraehenbuhl, J.P., Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu. Rev. Immunol. 14 (1996), 275–300.
173. [173] Valente, T.A., Silva, D.M., Gomes, P.S., Fernandes, M.H., Santos, J.D., Sencadas, V., Effect of sterilization methods on electrospun poly(lactic acid) (PLA) fiber alignment for biomedical applications. ACS Appl. Mater. Interf. 8 (2016), 3241–3249.
174. [174] Savaris, M., Santos, V.d., Brandalise, R.N., Influence of different sterilization processes on the properties of commercial poly(lactic acid). Mater. Sci. Eng., C 69 (2016), 661–667.
175. [175] Danoux, C.B., Barbieri, D., Yuan, H., de Bruijn, J.D., van Blitterswijk, C.A., Habibovic, P., In vitro and in vivo bioactivity assessment of a polylactic acid/hydroxyapatite composite for bone regeneration. Biomatter, 4, 2014, e27664.
176. [176] Cleland, J.L., Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol. 17 (1999), 25–29.
177. [177] Coombes, A.G., Lavelle, E.C., Jenkins, P.G., Davis, S.S., Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine 14 (1996), 1429–1438.
178. [178] Johansen, P., Moon, L., Tamber, H., Merkle, H.P., Gander, B., Sesardic, D., Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs. Vaccine 18 (1999), 209–215.
179. [179] Gupta, R.K., Goswami, D.G., Singh, R.R., Surolia, A., Panda, A.K., Soybean agglutinin coated PLA particles entrapping candidate vaccines induces enhanced primary and sustained secondary antibody response from single point immunization. Europ. J. Pharm. Sci.: Off. J. Europ. Feder. Pharm. Sci. 45 (2012), 282–295.
180. [180] Vila, A., Sanchez, A., Evora, C., Soriano, I., McCallion, O., Alonso, M.J., PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int. J. Pharm. 292 (2005), 43–52.
181. [181] Baxendale, A., van Hooff, P., Durrant, L.G., Spendlove, I., Howdle, S.M., Woods, H.M., Whitaker, M.J., Davies, O.R., Naylor, A., Lewis, A.L., Illum, L., Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology. Int. J. Pharm. 413 (2011), 147–154.
182. [182] A. Vila, A. Sanchez, C. Evora, I. Soriano, J.L. Vila Jato, M.J. Alonso, PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J. Aerosol Med.: Off. J. Int. Soc. Aerosols Med. 17 (2004) 174–185.
183. [183] Raghuvanshi, R.S., Katare, Y.K., Lalwani, K., Ali, M.M., Singh, O., Panda, A.K., Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int. J. Pharm. 245 (2002), 109–121.
184. [184] Johansen, P., Estevez, F., Zurbriggen, R., Merkle, H.P., Gluck, R., Corradin, G., Gander, B., Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine 19 (2000), 1047–1054.
185. [185] Anish, C., Goswami, D.G., Kanchan, V., Mathew, S., Panda, A.K., The immunogenic characteristics associated with multivalent display of Vi polysaccharide antigen using biodegradable polymer particles. Biomaterials 33 (2012), 6843–6857.
186. [186] Florindo, H.F., Pandit, S., Goncalves, L.M., Alpar, H.O., Almeida, A.J., New approach on the development of a mucosal vaccine against strangles: systemic and mucosal immune responses in a mouse model. Vaccine 27 (2009), 1230–1241.
187. [187] Florindo, H.F., Pandit, S., Goncalves, L.M., Videira, M., Alpar, O., Almeida, A.J., Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres. Biomaterials 30 (2009), 5161–5169.
188. [188] McCartney, S., Vermi, W., Gilfillan, S., Cella, M., Murphy, T.L., Schreiber, R.D., Murphy, K.M., Colonna, M., Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J. Exp. Med. 206 (2009), 2967–2976.
189. [189] Steinhagen, F., Kinjo, T., Bode, C., Klinman, D.M., TLR-based immune adjuvants. Vaccine 29 (2011), 3341–3355.
190. [190] Jain, A.K., Goyal, A.K., Gupta, P.N., Khatri, K., Mishra, N., Mehta, A., Mangal, S., Vyas, S.P., Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B. J. Control. Release: Off. J. Control. Release Soc. 136 (2009), 161–169.
191. [191] Jain, A.K., Goyal, A.K., Mishra, N., Vaidya, B., Mangal, S., Vyas, S.P., PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B. Int. J. Pharm. 387 (2010), 253–262.
192. [192] Lv, S., Wang, J., Dou, S., Yang, X., Ni, X., Sun, R., Tian, Z., Wei, H., Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection. Hepatology (Baltimore, Md) 59 (2014), 385–394.
193. [193] Thomas, C., Rawat, A., Hope-Weeks, L., Ahsan, F., Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol. Pharm. 8 (2011), 405–415.
194. [194] Pandit, S., Cevher, E., Zariwala, M.G., Somavarapu, S., Alpar, H.O., Enhancement of immune response of HBsAg loaded poly (L-lactic acid) microspheres against hepatitis B through incorporation of alum and chitosan. J. Microencapsul. 24 (2007), 539–552.
195. [195] Chen, X., Liu, Y., Wang, L., Liu, Y., Zhang, W., Fan, B., Ma, X., Yuan, Q., Ma, G., Su, Z., Enhanced humoral and cell-mediated immune responses generated by cationic polymer-coated PLA microspheres with adsorbed HBsAg. Mol. Pharm. 11 (2014), 1772–1784.
196. [196] Ataman-Onal, Y., Munier, S., Ganee, A., Terrat, C., Durand, P.Y., Battail, N., Martinon, F., Le Grand, R., Charles, M.H., Delair, T., Verrier, B., Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J. Control. Release: Off. J. Control. Release Soc. 112 (2006), 175–185.
197. [197] Aline, F., Brand, D., Pierre, J., Roingeard, P., Severine, M., Verrier, B., Dimier-Poisson, I., Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 27 (2009), 5284–5291.
198. [198] Guillon, C., Mayol, K., Terrat, C., Compagnon, C., Primard, C., Charles, M.H., Delair, T., Munier, S., Verrier, B., Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine 25 (2007), 7491–7501.
199. [199] Lamalle-Bernard, D., Munier, S., Compagnon, C., Charles, M.H., Kalyanaraman, V.S., Delair, T., Verrier, B., Ataman-Onal, Y., Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity. J. Control. Release: Off. J. Control. Release Soc. 115 (2006), 57–67.
200. [200] Liard, C., Munier, S., Arias, M., Joulin-Giet, A., Bonduelle, O., Duffy, D., Shattock, R.J., Verrier, B., Combadiere, B., Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine 29 (2011), 6379–6391.
201. [201] Pavot, V., Rochereau, N., Primard, C., Genin, C., Perouzel, E., Lioux, T., Paul, S., Verrier, B., Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. J. Control. Release: Off. J. Control. Release Soc. 167 (2013), 60–67.
202. [202] Thapa, P., Zhang, G., Xia, C., Gelbard, A., Overwijk, W.W., Liu, C., Hwu, P., Chang, D.Z., Courtney, A., Sastry, J.K., Wang, P.G., Li, C., Zhou, D., Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine 27 (2009), 3484–3488.
203. [203] Climent, N., Munier, S., Pique, N., Garcia, F., Pavot, V., Primard, C., Casanova, V., Gatell, J.M., Verrier, B., Gallart, T., Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. Vaccine 32 (2014), 6266–6276.
204. [204] Pavot, V., Climent, N., Rochereau, N., Garcia, F., Genin, C., Tiraby, G., Vernejoul, F., Perouzel, E., Lioux, T., Verrier, B., Paul, S., Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands. Biomaterials 75 (2016), 327–339.
205. [205] Chen, W.L., Liu, S.J., Leng, C.H., Chen, H.W., Chong, P., Huang, M.H., Disintegration and cancer immunotherapy efficacy of a squalane-in-water delivery system emulsified by bioresorbable poly(ethylene glycol)-block-polylactide. Biomaterials 35 (2014), 1686–1695.
206. [206] Men, Y., Gander, B., Merkle, H.P., Corradin, G., Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine 14 (1996), 1442–1450.
207. [207] Yeh, M., Chiang, C., Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: in vitro release and oral vaccination. J. Microencapsul. 21 (2004), 91–106.
208. [208] Coombes, A.G., Major, D., Wood, J.M., Hockley, D.J., Minor, P.D., Davis, S.S., Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines. Biomaterials 19 (1998), 1073–1081.
209. [209] Zhang, W., Wang, L., Liu, Y., Chen, X., Li, J., Yang, T., An, W., Ma, X., Pan, R., Ma, G., Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis. Pharm. Res. 31 (2014), 1015–1031.
210. [210] Yeh, M.K., Coombes, A.G., Chen, J.L., Chiang, C.H., Japanese encephalitis virus vaccine formulations using PLA lamellar and PLG microparticles. J. Microencapsul. 19 (2002), 671–682.
211. [211] Kissick, H.T., Sanda, M.G., The role of active vaccination in cancer immunotherapy: lessons from clinical trials. Curr. Opin. Immunol. 35 (2015), 15–22.
212. [212] Krishnamachari, Y., Geary, S.M., Lemke, C.D., Salem, A.K., Nanoparticle delivery systems in cancer vaccines. Pharm. Res. 28 (2011), 215–236.
213. [213] F. Puoci, Advanced Polymers in Medicine: Springer International Publishing, 2014.
214. [214] Fujii, S., Shimizu, K., Smith, C., Bonifaz, L., Steinman, R.M., Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198 (2003), 267–279.
215. [215] Dominguez, A.L., Lustgarten, J., Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine 28 (2010), 1383–1390.
216. [216] Egilmez, N.K., Jong, Y.S., Sabel, M.S., Jacob, J.S., Mathiowitz, E., Bankert, R.B., In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 60 (2000), 3832–3837.
217. [217] Sainz, V., Conniot, J., Matos, A.I., Peres, C., Zupancic, E., Moura, L., Silva, L.C., Florindo, H.F., Gaspar, R.S., Regulatory aspects on nanomedicines. Biochem. Biophys. Res. Commun. 468 (2015), 504–510.
218. [218] Etheridge, M.L., Campbell, S.A., Erdman, A.G., Haynes, C.L., Wolf, S.M., McCullough, J., The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9 (2013), 1–14.
219. [219] Khorasani, A.A., Weaver, J.L., Salvador-Morales, C., Closing the gap: accelerating the translational process in nanomedicine by proposing standardized characterization techniques. Int. J. Nanomed. 9 (2014), 5729–5751.
220. [220] Eaton, M.A., Levy, L., Fontaine, O.M., Delivering nanomedicines to patients: a practical guide. Nanomedicine 11 (2015), 983–992.
221. [221] Nystrom, A.M., Fadeel, B., Safety assessment of nanomaterials: implications for nanomedicine. J. Control. Release: Off. J. Control. Release Soc. 161 (2012), 403–408.
222. [222] Murday, J.S., Siegel, R.W., Stein, J., Wright, J.F., Translational nanomedicine: status assessment and opportunities. Nanomedicine 5 (2009), 251–273.